Clinical Research Directory
Browse clinical research sites, groups, and studies.
Study of Stapokibatrt in Children Subjects With Atopic Dermatitis
Sponsor: Keymed Biosciences Co.Ltd
Summary
This is a multi-center, randomized, double blind, placebo-controlled phase 3 study to evaluate the efficacy, safety, Pharmacokinetics(PK), PharmacoDynamics(PD) and immunogenicity of Stapokibatrt in children with moderate-to-severe atopic dermatitis.
Official title: A Randomized, Double-blind, Placebo-controlled Phase 3 Study to Evaluate the Efficacy and Safety of Stapokibatrt in Children With Moderate-to-severe Atopic Dermatitis
Key Details
Gender
All
Age Range
2 Years - 11 Years
Study Type
INTERVENTIONAL
Enrollment
240
Start Date
2025-05
Completion Date
2026-08
Last Updated
2025-05-04
Healthy Volunteers
No
Conditions
Interventions
Stapokibatrt
Stapokibatrt 1 or 2 ml,Subcutaneous injection(SC)
Placebo
Placebo of matching volume,Subcutaneous injection(SC)
Locations (1)
Beijing Children's Hospital Capital Medical University
Beijing, China